Citation
Visser, K. (2011, December 8). Towards improved treatment of undifferentiated and rheumatoid arthritis. Retrieved from https://hdl.handle.net/1887/18197
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/18197
Note: To cite this publication please use the final published version (if
applicable).
Towards Improved Treatment of
Undifferentiated and Rheumatoid Arthritis
Towards Improved Treatment of Undifferentiated and Rheumatoid Arthritis
PROEFSCHRIFT ter verkrijging van
de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties te verdedigen op donderdag 8 december 2011
klokke 13.45 uur
door Karen Visser geboren te Uburu, Nigerië
in 1980
COPROMOTOR dr. C.F. Allaart OVERIGE LEDEN Prof. dr. R. Brand
Prof. dr. F.W. Dekker Prof. dr. J.W.J. Bijlsma
Utrecht Medisch Centrum, Utrecht Prof. dr. R.B.M. Landewé
Academisch Medisch Centrum, Amsterdam
The research presented in this thesis was performed at the Rheumatology Department of the Leiden University Medical Center, Leiden, The
Netherlands. The research was financially supported by the Dutch College of Health Insurances, the Dutch Arthritis Foundation and by the Netherlands Organisation for Scientific Research, with additional funding by Schering-Plough B.V., Centocor Inc and ABBOTT B.V.
© Karen Visser, 2011.
karenvisser@hotmail.com
All rights reserved. No part of this thesis may be reproduced in any form without written permission from the author or, when appropriate, of the publishers of the publications.
ISBN 978-90-818281-0-9
Vormgeving: J.L.M de Veld, MediaCenter Rotterdam Druk: MediaCenter Rotterdam
The publication of this thesis was financially supported by ABBOTT B.V., Apotheekzorg, AstraZeneca B.V., Janssen Biologics B.V. (former Centocor B.V.), Merck Sharp & Dohme B.V., Novartis Pharma B.V., het Reumafonds, Roche Nederland B.V., Sandoz B.V., Sectra dxr-online, Schering-Plough B.V., Teva Pharma Nederland.
7
Contents
Chapter 1. General introduction
Part I. Improved treatment of undifferentiated arthritis Chapter 2. Efficacy of methotrexate treatment in patients with probable
rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial
Chapter 3. Disease activity, joint damage and functional disability and the effect of methotrexate treatment in patients with undifferentiated arthritis with or without anti-citrullinated protein antibodies
Chapter 4. Drug-free remission, relapse or persistent disease after discontinuation of methotrexate or placebo therapy in patients with undifferentiated arthritis
Chapter 5. Validity of the disease activity score in undifferentiated arthritisVV
Part II. Methotrexate in rheumatoid arthritis
Chapter 6. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the
3E initiative
Chapter 7. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
Chapter 8. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature
Part III. Improved treatment of rheumatoid arthritis
Chapter 9. A matrix risk model for the prediction of rapid radiographic progression in rheumatoid arthritis patients receiving different dynamic treatment strategies: Post-hoc analyses from the BeSt study Chapter 10. Sustained drug-free remission in rheumatoid arthritis after DAS-driven
or non-DAS-driven therapy: a comparison of two cohort studies Chapter 11. General discussion and conclusions
Nederlandse samenvatting Role of the funding source Acknowledgements List of publications Curriculum Vitae Dankwoord
